Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Grape King Bio Ltd. (1707:TWSE), powered by AI.
Grape King Bio Ltd. is currently trading at $99.70. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Grape King Bio Ltd. on Alpha Lenz.
Grape King Bio Ltd.'s P/E ratio is 12.1.
“Grape King Bio Ltd. trades at a P/E of 12.1 (undervalued) with solid ROE of 11.9%. Operating margin of 20.9% indicates strong profitability.”
Ask for details →Grape King Bio Ltd. is a notable player in the biotechnology and health food industry, primarily engaged in the production of probiotics, health supplements, and various functional foods. Its primary function is to innovate and manufacture products that enhance well-being by utilizing cutting-edge biotechnological advancements. The company's offerings are diversified across consumer health supplements, sports nutrition products, and specialty ingredients catering to diverse health needs and dietary preferences. Grape King Bio Ltd. serves a broad range of sectors, including food and beverage, pharmaceuticals, and health-focused retail industries, making its impact felt across multiple facets of consumer and health goods markets. With a strong presence in Taiwan and expanding reach in international markets, Grape King Bio Ltd. holds a significant role in driving forward advancements within the nutraceutical space, responding to the growing global demand for natural and effective health solutions.
“Grape King Bio Ltd. trades at a P/E of 12.1 (undervalued) with solid ROE of 11.9%. Operating margin of 20.9% indicates strong profitability.”
Ask for details →Grape King Bio Ltd. (ticker: 1707) is a company listed on TWSE in the Healthcare sector (Drug Manufacturers - Specialty & Generic). Market cap is $14.8B.
The current price is 99.7 with a P/E ratio of 12.12x and P/B of 1.43x.
ROE is 11.95% and operating margin is 20.88%. Annual revenue is $10.3B.